JP2014504851A5 - - Google Patents

Download PDF

Info

Publication number
JP2014504851A5
JP2014504851A5 JP2013540008A JP2013540008A JP2014504851A5 JP 2014504851 A5 JP2014504851 A5 JP 2014504851A5 JP 2013540008 A JP2013540008 A JP 2013540008A JP 2013540008 A JP2013540008 A JP 2013540008A JP 2014504851 A5 JP2014504851 A5 JP 2014504851A5
Authority
JP
Japan
Prior art keywords
nucleic acid
seq
polypeptide
bacterium
sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2013540008A
Other languages
English (en)
Japanese (ja)
Other versions
JP5998370B2 (ja
JP2014504851A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2011/061164 external-priority patent/WO2012068360A1/en
Publication of JP2014504851A publication Critical patent/JP2014504851A/ja
Publication of JP2014504851A5 publication Critical patent/JP2014504851A5/ja
Application granted granted Critical
Publication of JP5998370B2 publication Critical patent/JP5998370B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2013540008A 2010-11-17 2011-11-17 Egfrviiiに対する免疫応答を誘発する方法および組成物 Expired - Fee Related JP5998370B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US41485010P 2010-11-17 2010-11-17
US61/414,850 2010-11-17
PCT/US2011/061164 WO2012068360A1 (en) 2010-11-17 2011-11-17 Methods and compositions for inducing an immune response to egfrviii

Publications (3)

Publication Number Publication Date
JP2014504851A JP2014504851A (ja) 2014-02-27
JP2014504851A5 true JP2014504851A5 (enExample) 2015-01-08
JP5998370B2 JP5998370B2 (ja) 2016-09-28

Family

ID=46084412

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013540008A Expired - Fee Related JP5998370B2 (ja) 2010-11-17 2011-11-17 Egfrviiiに対する免疫応答を誘発する方法および組成物

Country Status (17)

Country Link
US (3) US9200057B2 (enExample)
EP (1) EP2640842B1 (enExample)
JP (1) JP5998370B2 (enExample)
CN (1) CN103415620B (enExample)
CA (1) CA2818353A1 (enExample)
CY (1) CY1120622T1 (enExample)
DK (1) DK2640842T3 (enExample)
ES (1) ES2684684T3 (enExample)
HR (1) HRP20181343T1 (enExample)
HU (1) HUE039747T2 (enExample)
LT (1) LT2640842T (enExample)
PL (1) PL2640842T3 (enExample)
PT (1) PT2640842T (enExample)
RS (1) RS57630B1 (enExample)
SI (1) SI2640842T1 (enExample)
SM (1) SMT201800444T1 (enExample)
WO (1) WO2012068360A1 (enExample)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2807552A1 (en) 2010-08-06 2012-02-09 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
EP3431485B2 (en) 2010-10-01 2024-09-04 ModernaTX, Inc. Engineered nucleic acids and methods of use thereof
ES2684684T3 (es) * 2010-11-17 2018-10-04 Aduro Biotech, Inc. Métodos y composiciones para inducir una respuesta inmune al EGFRVIII
WO2012135805A2 (en) 2011-03-31 2012-10-04 modeRNA Therapeutics Delivery and formulation of engineered nucleic acids
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
EP2763701B1 (en) 2011-10-03 2018-12-19 Moderna Therapeutics, Inc. Modified nucleosides, nucleotides, and nucleic acids, and uses thereof
KR20140102759A (ko) 2011-12-16 2014-08-22 모더나 세라퓨틱스, 인코포레이티드 변형된 뉴클레오사이드, 뉴클레오타이드 및 핵산 조성물
US9878056B2 (en) 2012-04-02 2018-01-30 Modernatx, Inc. Modified polynucleotides for the production of cosmetic proteins and peptides
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
DE18200782T1 (de) 2012-04-02 2021-10-21 Modernatx, Inc. Modifizierte polynukleotide zur herstellung von proteinen im zusammenhang mit erkrankungen beim menschen
AU2013271375B2 (en) 2012-06-08 2018-03-22 Aduro Biotech, Inc. Compositions and methods for cancer immunotherapy
HK1213008A1 (zh) 2012-11-06 2016-06-24 艾杜罗生物科技公司 兼性减毒细菌种类及其制备和使用方法
CA2892529C (en) 2012-11-26 2023-04-25 Moderna Therapeutics, Inc. Terminally modified rna
AU2013358892B2 (en) 2012-12-13 2018-06-21 Aduro Biotech, Inc. Compositions comprising cyclic purine dinucleotides having defined stereochemistries and methods for their preparation and use
SG10201700916SA (en) 2012-12-27 2017-03-30 Aduro Biotech Inc Signal peptide fusion partners facilitating listerial expression of antigenic sequences and methods of preparation and use thereof
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
ES2822584T3 (es) 2013-05-03 2021-05-04 Univ California Inducción de dinucleótidos cíclicos del interferón tipo I
US9549944B2 (en) 2013-05-18 2017-01-24 Aduro Biotech, Inc. Compositions and methods for inhibiting “stimulator of interferon gene”—dependent signalling
PE20160080A1 (es) 2013-05-18 2016-02-21 Aduro Biotech Inc Composiciones y metodos para activar la senalizacion que depende del estimulador del gen de interferon
US10023626B2 (en) 2013-09-30 2018-07-17 Modernatx, Inc. Polynucleotides encoding immune modulating polypeptides
EA201690675A1 (ru) 2013-10-03 2016-08-31 Модерна Терапьютикс, Инк. Полинуклеотиды, кодирующие рецептор липопротеинов низкой плотности
MA39849A (fr) * 2014-04-24 2017-03-01 Advaxis Inc Souches de listeria utilisées comme vaccin recombinant et procédé de production
US10925945B2 (en) 2014-10-13 2021-02-23 Providence Health & Services-Oregon Bacterial vaccines deficient in the 2-C-methyl-D-erythritol-4-phosphate pathway and methods of preparation and use thereof
US20160228530A1 (en) * 2014-10-14 2016-08-11 The Trustees Of The University Of Pennsylvania Combination therapy for use in cancer therapy
US10688166B2 (en) 2014-11-03 2020-06-23 Cerus Corporation Compositions and methods for improved car-T cell therapies
US10449211B2 (en) 2015-03-10 2019-10-22 Aduro Biotech, Inc. Compositions and methods for activating “stimulator of interferon gene”—dependent signalling
HK1250731A1 (zh) 2015-04-13 2019-01-11 艾杜罗生物科技公司 用於治疗癌症的免疫原性融合蛋白
SG11201708360TA (en) * 2015-04-13 2017-11-29 Aduro Biotech Inc Epidermal growth factor receptor variant iii-mesothelin fusions and methods of using the same
US20160316247A1 (en) * 2015-04-27 2016-10-27 Ericsson Ab Program and device class entitlements in a media platform
CA2987239A1 (en) * 2015-05-26 2016-12-01 Advaxis, Inc. Personalized delivery vector-based immunotherapy and uses thereof
EP3313975A4 (en) * 2015-06-24 2019-03-13 Advaxis, Inc. MANUFACTURING DEVICE AND METHOD FOR PERSONALIZED ADMINISTRATION OF VECTOR-BASED IMMUNOTHERAPY
CN108601731A (zh) 2015-12-16 2018-09-28 磨石肿瘤生物技术公司 新抗原的鉴别、制造及使用
NL2017267B1 (en) 2016-07-29 2018-02-01 Aduro Biotech Holdings Europe B V Anti-pd-1 antibodies
CN109890834A (zh) * 2016-08-01 2019-06-14 艾杜罗生物科技公司 蛋白质表达增强子序列及其用途
NL2017270B1 (en) 2016-08-02 2018-02-09 Aduro Biotech Holdings Europe B V New anti-hCTLA-4 antibodies
EP4576103A3 (en) 2017-10-10 2025-08-27 Gritstone bio, Inc. Neoantigen identification using hotspots
EP3714275A4 (en) 2017-11-22 2021-10-27 Gritstone bio, Inc. REDUCTION OF JUNCTION EPITOPIC PRESENTATION FOR NEOANTIGENS
WO2021014398A1 (en) * 2019-07-23 2021-01-28 University Of Rijeka Faculty Of Medicine Integrated human cytomegalovirus / glioblastoma vaccine

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5830702A (en) 1990-10-31 1998-11-03 The Trustees Of The University Of Pennsylvania Live, recombinant listeria monocytogenes and production of cytotoxic T-cell response
US5783415A (en) 1991-03-29 1998-07-21 Genentech, Inc. Method of producing an IL-8 receptor polypeptide
IT1262895B (it) 1992-03-02 1996-07-22 Proteina estratta da ceppi citotossici di helicobacter pylori, gene che la esprime, uso della proteina come vaccino o diagnostico.
US6379943B1 (en) 1999-03-05 2002-04-30 Merck & Co., Inc. High-efficiency Cre/loxp based system for construction of adenovirus vectors
US5709999A (en) * 1994-08-12 1998-01-20 Myriad Genetics Inc. Linked breast and ovarian cancer susceptibility gene
US6051237A (en) 1994-11-08 2000-04-18 The Trustees Of The University Of Pennsylvania Specific immunotherapy of cancer using a live recombinant bacterial vaccine vector
US7794729B2 (en) * 1994-11-08 2010-09-14 The Trustees Of The University Of Pennsylvania Methods and compositions for immunotherapy of cancer
DE69532767T2 (de) * 1994-11-28 2004-08-12 Thomas Jefferson University Peptid umfassend eine Sequenz aus einer Fusionsverbindungsstelle in einem mutierten EGF-Rezeptor vom Typ III
WO1997003715A1 (en) 1995-07-21 1997-02-06 The General Hospital Corporation Method and apparatus of enhancing the delivery of a pharmaceutical formulation
US6099848A (en) 1997-11-18 2000-08-08 The Trustees Of The University Of Pennsylvania Immunogenic compositions comprising DAL/DAT double-mutant, auxotrophic, attenuated strains of Listeria and their methods of use
CN1511040A (zh) * 2001-05-25 2004-07-07 ����˹���ѷ��ѧ 作为多种治疗模式基础的蛋白质的选择性剪接形式
JP2005527240A (ja) 2002-05-29 2005-09-15 ザ・レジェンツ・オブ・ザ・ユニバーシティ・オブ・カリフォルニア 弱毒リステリア種とこれを使用する方法
US20050175625A1 (en) 2002-07-12 2005-08-11 The Johns Hopkins University Mesothelin vaccines and model systems
WO2004084936A2 (en) 2003-02-06 2004-10-07 Cerus Corporation Modified free-living microbes, vaccine compositions and methods of use thereof
PT1592441E (pt) 2003-02-06 2012-05-21 Aduro Biotech Listeria atenuada relativamente à entrada em células não patogénicas, vacinas compreendendo a listeria e métodos para sua utilização
US7842289B2 (en) 2003-12-24 2010-11-30 Aduro Biotech Recombinant nucleic acid molecules, expression cassettes, and bacteria, and methods of use thereof
CN104857500A (zh) * 2005-11-02 2015-08-26 杜克大学 同时的化学疗法和免疫疗法
EP1991263B8 (en) * 2006-03-01 2015-02-25 Aduro Biotech Engineered listeria and methods of use thereof
WO2007117371A2 (en) 2006-03-01 2007-10-18 Anza Therapeutics, Inc. Engineered listeria and methods of use thereof
WO2009012488A1 (en) * 2007-07-19 2009-01-22 Duke University Assay for human anti-egrf variant iii antibodies
CN102076843A (zh) * 2008-05-19 2011-05-25 艾杜罗生物科技公司 包含prfa*突变体李斯特菌的组合物及其使用方法
US20120100170A1 (en) * 2008-07-24 2012-04-26 Lauer Peter M Compositions and methods for the treatment of hepatitis c
TWI580431B (zh) * 2008-08-19 2017-05-01 腫瘤療法 科學股份有限公司 Hig2與urlc10抗原決定位胜肽以及含此胜肽之疫苗
ES2684684T3 (es) * 2010-11-17 2018-10-04 Aduro Biotech, Inc. Métodos y composiciones para inducir una respuesta inmune al EGFRVIII

Similar Documents

Publication Publication Date Title
JP2014504851A5 (enExample)
Crocquet-Valdes et al. Immunization with a portion of rickettsial outer membrane protein A stimulates protective immunity against spotted fever rickettsiosis
JP2010508861A (ja) 抗原およびタンパク質毒素をコードする異種ヌクレオチド配列からなる担体としての微生物、その生成方法、ならびにその使用
CN102046198A (zh) 鞭毛蛋白多肽疫苗
RU2677799C2 (ru) Модифицированные суперспиральные белки с улучшенными свойствами
KR20160130216A (ko) 헤테로올리고머 미코박테리아 항원의 융합물
JP2011529077A (ja) C型肝炎の治療のための組成物および方法
JP2009540801A5 (enExample)
JP2014507146A5 (enExample)
JP2012515557A5 (enExample)
TWI621627B (zh) 用於豬生殖與呼吸綜合症及豬環狀病毒關聯疾病之疫苗組成物
CN103013954B (zh) 水稻基因badh2的定点敲除系统及其应用
JP2018501260A (ja) 人工多抗原融合タンパク質およびその製造と使用
WO2007125535A1 (en) Recombinant flagellin gene and uses thereof
CN101128480A (zh) 含有缺损的鞭毛蛋白基因的革兰氏阳性菌细胞、基于鞭毛蛋白的融合蛋白以及从液体中除去金属离子的用途
Kim et al. Expression of Helicobacter pylori cag12 gene in Lactococcus lactis MG1363 and its oral administration to induce systemic anti-Cag12 immune response in mice
US9925259B2 (en) Immunogenic polypeptide surface layer-expressing bifidobacterium
CN107723269B (zh) 重组鼠伤寒沙门菌二价疫苗株的构建方法及所得株和应用
Zhou et al. A novel multivalent vaccine based on secretary antigen-delivery induces protective immunity against Vibrio anguillarum and Aeromonas hydrophila
EP4196158A1 (en) Salmonella vaccine for the treatment of coronavirus
CA2730741C (en) Self-replicating vector lacking an antibiotic-resistance gene
Kim et al. Oral administration of Lactococcus lactis expressing Helicobacter pylori Cag7-ct383 protein induces systemic anti-Cag7 immune response in mice
EP3562504B1 (en) Dna vaccine comprising a polynucleotide sequence encoding a fusion protein encompassing a plant protein signal sequence
WO2009127766A1 (es) Sistema para la expresión de péptidos sobre la superficie bacteriana
Borovkov et al. New classes of orthopoxvirus vaccine candidates by functionally screening a synthetic library for protective antigens